These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 3659033)

  • 1. Wait and see: experience with B1 lesions.
    Whitmore WF; Rosenberg S; Chopp R
    Prog Clin Biol Res; 1987; 243B():387-94. PubMed ID: 3659033
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prostatic cancer: pathological analysis of autopsied cases].
    Takahashi Y; Mayuzumi T; Satoh J
    Hinyokika Kiyo; 1986 Jun; 32(6):835-9. PubMed ID: 3766343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Histopathological diagnosis of prostatic cancer].
    Wasilewski A; Szymanowski J
    Pol Tyg Lek; 1981 Jun; 36(25):909-11. PubMed ID: 7301641
    [No Abstract]   [Full Text] [Related]  

  • 4. [Study of surgically removed pelvic lymph nodes in the staging of prostatic carcinoma].
    Hoekstra JW; Schröder FH
    Ned Tijdschr Geneeskd; 1982 Dec; 126(50):2291-4. PubMed ID: 7155208
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence of silent prostatic adenocarcinoma in 165 patients undergone cystoprostatectomy: a retrospective study.
    Cindolo L; Benincasa G; Autorino R; Domizio S; De Rosa G; Testa G; D'Armiento M; Altieri V
    Oncol Rep; 2001; 8(2):269-71. PubMed ID: 11182038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostatic cancer. Reliability of clinical staging and the prognostic significance of age, clinical stage and tumor morphology].
    Mihatsch MJ; Rist M; Ohnacker H; Oberholzer M; Spichtin HP; Schmassmann A; Perret A; Torhorst J; Rutishauser G
    Z Urol Nephrol; 1983 May; 76(5):281-97. PubMed ID: 6880416
    [No Abstract]   [Full Text] [Related]  

  • 7. Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
    Forman JD; Lee WR; Roach M; Perez CA; Beyer DC; Blasko JC; Hussey DH; Paryani SB; Pollack A; Potters L; Scardino P; Schellhammer P; Leibel S
    Radiology; 2000 Jun; 215 Suppl():1373-82. PubMed ID: 11037553
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Alhava E; Syrjänen K
    Anticancer Res; 1994; 14(2B):709-14. PubMed ID: 8010731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis, staging, and surgical treatment of prostatic carcinoma.
    Catalona WJ; Avioli LV
    Arch Intern Med; 1987 Feb; 147(2):361-3. PubMed ID: 3813756
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prognostic value of clinical staging of prostatic cancer with regard to the degree of histopathological malignancy].
    Szymanowski J; Wasilewski A
    Pol Tyg Lek; 1982 Jul; 37(24-25):709-12. PubMed ID: 7177967
    [No Abstract]   [Full Text] [Related]  

  • 11. [Morphology of prostate carcinoma in biopsies and total prostatectomies. Relevance of biopsy findings].
    Kastendieck H
    Pathologe; 1980 Nov; 2(1):31-43. PubMed ID: 7465545
    [No Abstract]   [Full Text] [Related]  

  • 12. [Functional results and oncologic control after anatomic radical prostatectomy].
    Rohner S; Graber P
    Ann Urol (Paris); 1994; 28(4):190-5. PubMed ID: 7979208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent data about prostatic carcinoma (author's transl)].
    Coune A
    Rev Med Brux; 1980 May; 1(5):311-4. PubMed ID: 7466030
    [No Abstract]   [Full Text] [Related]  

  • 14. Nodal involvement as prognostic indicator in prostatic carcinoma.
    Prout GR; Griffin PP; Daly JJ; Shipley WU
    Urology; 1981 Mar; 17(Suppl 3):72-9. PubMed ID: 7210370
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.
    Abrahamsson PA; Cockett AT; di Sant'Agnese PA
    Prostate Suppl; 1998; 8():37-42. PubMed ID: 9690662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low grade adenocarcinoma simulating benign glandular lesions in needle prostatic biopsy.
    Arista-Nasr J; Cortés E; Pichardo R
    Rev Invest Clin; 1997; 49(1):37-40. PubMed ID: 9114721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour.
    Lipponen P; Vesalainen S; Kasurinen J; Ala-Opas M; Syrjänen K
    Anticancer Res; 1996; 16(4A):2095-100. PubMed ID: 8712749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging of M0 prostatic adenocarcinoma: how aggressive should one be?
    Olsson CA
    Prog Clin Biol Res; 1984; 153():455-67. PubMed ID: 6473408
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathologic characteristics of prostatic adenocarcinomas: a mapping analysis of Korean patients.
    Song SY; Kim SR; Ahn G; Choi HY
    Prostate Cancer Prostatic Dis; 2003; 6(2):143-7. PubMed ID: 12806373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.